azd-6280
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00681746)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GABA receptor alpha-3 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRA3 positive allosteric modulator
- GABA receptor alpha-2 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRA2 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N- Mol. weight
- 366.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1783256 ↗
Also known as
- 4-amino-8-(2,5-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide
- azd6280
- azd6280
- azd6280
- azd-6280
- azd-6280
- azd-6280
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00824057 | Phase 1 | Jan 1, 2009 | AstraZeneca, IQVIA |
| NCT00750802 | Phase 1 | Sep 1, 2008 | AstraZeneca |
| NCT00681317 | Phase 1 | Mar 1, 2008 | AstraZeneca |
| NCT00681746 | Phase 1 | Feb 1, 2008 | AstraZeneca |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 1 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1